2,764
Views
15
CrossRef citations to date
0
Altmetric
Research Paper

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers

, ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, , & ORCID Icon show all
Article: 1953344 | Received 20 Apr 2021, Accepted 03 Jul 2021, Published online: 29 Jul 2021

References

  • Atici S, ÖF E, Yildiz MS, Şikgenç MM, Güzel E, Soysal A. Symptomatic recurrence of SARS-CoV-2 infection in healthcare workers recovered from COVID-19. J Infect Dev Ctries. 2021 Jan 31;15(1):3876–3880. doi:10.3855/jidc.14305.
  • World Health Organization. Draft landscape of COVID-19 candidate vaccines. [accessed 2020 Oct 20]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
  • The Turkish Ministry of Health Covid19 information page. [accessed 13 Apr 2021]. https://covid19asi.saglik.gov.tr/?_Dil=2.
  • Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529):eabf4063. doi:10.1126/science.abf4063.
  • Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. [accessed 2021 Mar 3]. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html.
  • Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermúdez-González MC, Bielak DA, Carreño JM, Chernet RL, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021 Apr 8;384(14):1372–74. doi:10.1056/NEJMc2101667.
  • Gönüllü E, Soysal A, Can İ, Tutak E, Tunç T, Yıldız İ, Yeşilbaş O, Öner N, Anarat A, Soysal FG, et al. The use of social network in daily pediatric practice and education: Turkish pediatric atelier. Int J Pediatr. 2020 Sep 21;2020:7301309. doi:10.1155/2020/7301309.
  • Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181–92. doi:10.1016/S1473-3099(20)30843-4.
  • Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, Randell P, Pria AD, Lightstone L, Xu XN, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
  • Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T, Noursadeghi M, Boyton RJ, Semper A, Moon JC, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021 Mar 20;397(10279):1057–58. doi:10.1016/S0140-6736(21)00501-8.
  • Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD,Sajadi MM. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021 Apr 13;325(14):1467–69. doi:10.1001/jama.2021.3341.
  • Bradley T, Grundberg E, Selvarangan R, LeMaster C, Fraley E, Banerjee D, Belden B, Louiselle D, Nolte N, Biswell R, et al. Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021 May 20;384(20):1959–61. doi:10.1056/NEJMc2102051.
  • Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, Frias EC, Stewart JL, Van Eyk JE, Braun JG, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021 Apr 1;27:981–84. doi:10.1038/s41591-021-01325-6.
  • Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussières G, Brassard N, Laumaea A, Vézina D, Prévost J et al. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. bioRxiv [Preprint]. 2021 Mar 18: 2021.03.18.435972.
  • Thiagarajan K. What do we know about India’s Covaxin vaccine? BMJ 2021 Apr 20;373:n997. doi:10.1136/bmj.n997.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.